Piramal Pharma (PPLPHARMA) | Stock Overview & Key Data
Piramal Pharma Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹307.90 on November 4, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Dividend Information
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Piramal Pharma
PPLPHARMA
|
199.68B Mid-cap | -6.68% | 4.13% | 9.23% | -9.90% | -1.74% | -16.24% | 115.91% | 3.17% | 3.17% | 3.17% | 3.17% |
|
Sun Pharmaceutical
SUNPHARMA
|
3.88T Large-cap | -2.77% | -1.84% | 2.13% | -0.53% | 4.00% | 7.25% | 79.99% | 166.96% | 144.01% | 669.48% | 2,278.32% |
|
Divi's Laboratories
DIVISLAB
|
1.69T Large-cap | -3.26% | -1.31% | 2.02% | 1.80% | 2.98% | 0.83% | 89.86% | 56.44% | 484.44% | 1,625.50% | 9,907.51% |
|
Eris Lifesciences
ERIS
|
193.36B Mid-cap | 0.05% | 0.63% | 0.12% | -13.23% | -9.28% | -11.56% | 119.21% | 94.70% | 132.59% | 132.59% | 132.59% |
|
Neuland Laboratories
NEULANDLAB
|
184.81B Mid-cap | -0.95% | 4.87% | 29.12% | 3.39% | 12.28% | 48.55% | 510.11% | 716.28% | 2,058.53% | 16,354.50% | 19,900.00% |
|
Natco Pharma
NATCOPHARM
|
191.91B Mid-cap | -20.80% | -15.73% | -1.77% | 0.72% | 5.75% | 15.00% | 61.82% | -2.35% | 95.99% | 1,726.50% | 4,758.44% |
Ownership & Short Interest
Calculate Your Piramal Pharma Investment Returns
Long-Term Investment Performance Analysis
Piramal Pharma stock price in Oct 2022 was ₹167.48, A ₹1,000.00 lump sum investment in Piramal Pharma made 3 years ago would be worth approximately ₹997.19 today, representing a negative return of -0.28%. This translates to an annualized return (CAGR) of -0.08%.
3 Years 7 Months Investment Scenario (Oct 2022 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is PPLPHARMA's 52-week high and low?
- In the last 52 weeks, Piramal Pharma reached a high of ₹220.85 (on July 17, 2025) and a low of ₹132.30 (on March 23, 2026).
- What is the market cap and P/E ratio for PPLPHARMA?
- Curious about Piramal Pharma's size and valuation? Its market capitalization stands at 199.68B. When it comes to valuation, the P/E ratio (trailing twelve months) is 269.79, and the forward P/E (looking ahead) is 67.23.
- Does PPLPHARMA pay dividends? If so, what's the yield?
- Yes, Piramal Pharma is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.07%, and the company has paid an average of ₹0.08 per share annually over the past 3 years.
- Who are Piramal Pharma's main competitors or similar companies to consider before investing?
When looking at Piramal Pharma, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.88T Healthcare Drug Manufacturers - Specialty & Generic 7.25% 79.99% Divi's Laboratories
DIVISLAB1.69T Healthcare Drug Manufacturers - Specialty & Generic 0.83% 89.86% Eris Lifesciences
ERIS193.36B Healthcare Drug Manufacturers - Specialty & Generic -11.56% 119.21% Neuland Laboratories
NEULANDLAB184.81B Healthcare Drug Manufacturers - Specialty & Generic 48.55% 510.11% Natco Pharma
NATCOPHARM191.91B Healthcare Drug Manufacturers - Specialty & Generic 15.00% 61.82% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Piramal Pharma Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Piramal Pharma's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 1.12%, the Debt to Equity ratio from the most recent quarter is 60.08, and its Gross Profit Margin stands at 63.25%.
- What is the recent revenue and earnings growth for PPLPHARMA?
- Looking at Piramal Pharma's growth, its revenue over the trailing twelve months (TTM) was INR89B. Compared to the same quarter last year (YoY), quarterly revenue grew by -2.90%, and quarterly earnings saw a YoY growth of -4.54%.
- How much of PPLPHARMA stock is held by insiders and institutions?
- Wondering who owns Piramal Pharma stock? Company insiders (like executives and directors) hold about 54.54% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 20.41%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.